CXCR4 and Familial prostate cancer: A limited number of pre-clinical studies have demonstrated that the inhibition of the CXCR4/CXCL12 pathway using CXCR4 antagonists, including Plerixafor and CTCE-9908, reduced bone metastatic burden in breast and prostate cancer models [47,48,49].